Results 171 to 180 of about 12,991 (277)

HEREDITARY FAMILIAL NEPHRITIS

open access: yesNihon Naika Gakkai Zasshi, 1972
Yasuo HASHIMOTO   +8 more
openaire   +2 more sources

Real‐world efficacy and toxicity of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma according to IMDC risk criteria—A multi‐center retrospective analysis on behalf of the GUARDIANS group

open access: yesInternational Journal of Cancer, Volume 158, Issue 9, Page 2440-2451, 1 May 2026.
What's new? The combination of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma has demonstrated durable response and tolerability in clinical trials. However, inclusion criteria for clinical studies are restrictive, and patients in the real‐world setting tend to have more comorbidities.
Hendrik Dinkel   +21 more
wiley   +1 more source

Carbohydrate‐Based Drug Discovery: Synthetic Strategies and Clinical Applications

open access: yesIsrael Journal of Chemistry, Volume 66, Issue 3, May 2026.
The picture depicts the molecules discussed in the review. On the left side, the general scaffold of sugars is shown. Next to it are four carbohydrate‐based molecules, including remdesivir, islatravir, empagliflozin, and Globo‐H. Remdesivir and islatravir contain a substituted ribose ring attached to a modified nucleobase.
Stephan Scheeff   +2 more
wiley   +1 more source

Alport Syndrome: A Specific Case of Hereditary Nephropathy

open access: yesSaudi Journal of Kidney Diseases and Transplantation, 1999
Cohan Eric
doaj  

A rare case of dual glomerular pathology: Alport syndrome and immune complex-mediated MPGN. [PDF]

open access: yesBMC Nephrol
Ozcan SG   +6 more
europepmc   +1 more source

Clinical features of hearing loss and genotype-phenotype correlations in Alport syndrome caused by COL4A4 or COL4A5 variants. [PDF]

open access: yesSci Rep
Matsuzaki S   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy